APOE and PCMT1 |
apolipoprotein E |
protein-L-isoaspartate (D-aspartate) O-methyltransferase |
- Lipoprotein metabolism
- Metabolism of lipids and lipoproteins
- Chylomicron-mediated lipid transport
- Lipid digestion, mobilization, and transport
- Diseases associated with visual transduction
- HDL-mediated lipid transport
- Visual phototransduction
- Scavenging by Class A Receptors
- Retinoid metabolism and transport
|
|
- Human Serum Albumin
- Serum albumin iodonated
|
- S-Adenosyl-L-Homocysteine
|
|
|
APOE and RHEB |
apolipoprotein E |
Ras homolog enriched in brain |
- Lipoprotein metabolism
- Metabolism of lipids and lipoproteins
- Chylomicron-mediated lipid transport
- Lipid digestion, mobilization, and transport
- Diseases associated with visual transduction
- HDL-mediated lipid transport
- Visual phototransduction
- Scavenging by Class A Receptors
- Retinoid metabolism and transport
|
- Insulin receptor signalling cascade
- IRS-mediated signalling
- Regulation of Rheb GTPase activity by AMPK
- mTOR signalling
- S6K1-mediated signalling
- IRS-related events
- mTOR signalling
- Release of eIF4E
- mTORC1-mediated signalling
- IGF1R signaling cascade
- S6K1-mediated signalling
- mTORC1-mediated signalling
- IRS-related events triggered by IGF1R
- IRS-mediated signalling
- Release of eIF4E
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Energy dependent regulation of mTOR by LKB1-AMPK
- PKB-mediated events
- PI3K Cascade
- PKB-mediated events
- PI3K Cascade
- Signaling by Insulin receptor
|
- Human Serum Albumin
- Serum albumin iodonated
|
|
|
|
APOE and LRP8 |
apolipoprotein E |
low density lipoprotein receptor-related protein 8, apolipoprotein e receptor |
- Lipoprotein metabolism
- Metabolism of lipids and lipoproteins
- Chylomicron-mediated lipid transport
- Lipid digestion, mobilization, and transport
- Diseases associated with visual transduction
- HDL-mediated lipid transport
- Visual phototransduction
- Scavenging by Class A Receptors
- Retinoid metabolism and transport
|
- Visual phototransduction
- Platelet homeostasis
- Platelet sensitization by LDL
- Diseases associated with visual transduction
- Retinoid metabolism and transport
|
- Human Serum Albumin
- Serum albumin iodonated
|
|
|
|
BCL2L1 and PSEN1 |
BCL2-like 1 |
presenilin 1 |
- Inflammasomes
- The NLRP1 inflammasome
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Programmed Cell Death
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Innate Immune System
- Intrinsic Pathway for Apoptosis
|
- Degradation of the extracellular matrix
|
|
|
|
|
CACNA1A and HECW1 |
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 |
- Integration of energy metabolism
- Regulation of insulin secretion
- Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels
- Transmission across Chemical Synapses
|
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- degradation of DVL
- Signaling by Wnt
- Signaling by WNT in cancer
|
- Pregabalin
- Verapamil
- Loperamide
- Bepridil
|
|
|
|
CACNA1A and RIMBP2 |
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
RIMS binding protein 2 |
- Integration of energy metabolism
- Regulation of insulin secretion
- Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels
- Transmission across Chemical Synapses
|
|
- Pregabalin
- Verapamil
- Loperamide
- Bepridil
|
|
|
|
CASP1 and PSEN1 |
caspase 1, apoptosis-related cysteine peptidase |
presenilin 1 |
- Signaling by Interleukins
- The NLRP3 inflammasome
- Inflammasomes
- NOD1/2 Signaling Pathway
- The AIM2 inflammasome
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Interleukin-1 processing
- The IPAF inflammasome
- Cytokine Signaling in Immune system
- Innate Immune System
|
- Degradation of the extracellular matrix
|
- Minocycline
- 1-METHYL-3-TRIFLUOROMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE
- 3-[2-(2-BENZYLOXYCARBONYLAMINO-3-METHYL-BUTYRYLAMINO)-PROPIONYLAMINO]-4-OXO-PENTANOIC ACID
- 3-{6-[(8-HYDROXY-QUINOLINE-2-CARBONYL)-AMINO]-2-THIOPHEN-2-YL-HEXANOYLAMINO}-4-OXO-BUTYRI ACID
|
|
|
|
CASP3 and PSEN1 |
caspase 3, apoptosis-related cysteine peptidase |
presenilin 1 |
- SMAC binds to IAPs
- SMAC-mediated dissociation of IAP:caspase complexes
- SMAC-mediated apoptotic response
- Cytochrome c-mediated apoptotic response
- Caspase-mediated cleavage of cytoskeletal proteins
- Degradation of the extracellular matrix
- Role of DCC in regulating apoptosis
- Activation of caspases through apoptosome-mediated cleavage
- Activation of DNA fragmentation factor
- Apoptotic factor-mediated response
- Programmed Cell Death
- Intrinsic Pathway for Apoptosis
- Signalling by NGF
- Apoptotic cleavage of cellular proteins
- Cell death signalling via NRAGE, NRIF and NADE
- Apoptotic execution phase
- p75 NTR receptor-mediated signalling
- Stimulation of the cell death response by PAK-2p34
- Apoptotic cleavage of cell adhesion proteins
- Signaling by Hippo
- Apoptosis induced DNA fragmentation
- Extrinsic Pathway
- NADE modulates death signalling
|
- Degradation of the extracellular matrix
|
- Minocycline
- 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
- 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
- methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
- 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
- [N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID
- 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
- (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- N-[3-(2-fluoroethoxy)phenyl]-N\'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
|
|
|
|
CASP4 and PSEN1 |
caspase 4, apoptosis-related cysteine peptidase |
presenilin 1 |
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- NOD1/2 Signaling Pathway
- Innate Immune System
|
- Degradation of the extracellular matrix
|
|
|
|
|
CASP6 and PSEN1 |
caspase 6, apoptosis-related cysteine peptidase |
presenilin 1 |
- Apoptotic cleavage of cellular proteins
- Programmed Cell Death
- Apoptotic execution phase
- Breakdown of the nuclear lamina
- Caspase-mediated cleavage of cytoskeletal proteins
|
- Degradation of the extracellular matrix
|
|
|
|
|
CASP7 and PSEN1 |
caspase 7, apoptosis-related cysteine peptidase |
presenilin 1 |
- Activation of caspases through apoptosome-mediated cleavage
- Apoptotic cleavage of cellular proteins
- Apoptotic factor-mediated response
- SMAC binds to IAPs
- Apoptotic execution phase
- Programmed Cell Death
- SMAC-mediated dissociation of IAP:caspase complexes
- Cytochrome c-mediated apoptotic response
- SMAC-mediated apoptotic response
- Caspase-mediated cleavage of cytoskeletal proteins
- Intrinsic Pathway for Apoptosis
|
- Degradation of the extracellular matrix
|
|
|
|
|
CDK5 and PSEN1 |
cyclin-dependent kinase 5 |
presenilin 1 |
- Signaling by GPCR
- Axon guidance
- Semaphorin interactions
- Opioid Signalling
- DARPP-32 events
- CRMPs in Sema3A signaling
- Factors involved in megakaryocyte development and platelet production
|
- Degradation of the extracellular matrix
|
- Indirubin-3\'-Monoxime
- Olomoucine
- Hymenialdisine
- SU9516
- Flavopiridol
- Alsterpaullone
- 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
|
|
|
|
CFL1 and PSEN1 |
cofilin 1 (non-muscle) |
presenilin 1 |
- Axon guidance
- Semaphorin interactions
- Platelet degranulation
- EPHB-mediated forward signaling
- Response to elevated platelet cytosolic Ca2+
- Sema3A PAK dependent Axon repulsion
- EPH-Ephrin signaling
- Platelet activation, signaling and aggregation
- Fcgamma receptor (FCGR) dependent phagocytosis
- Regulation of actin dynamics for phagocytic cup formation
- Innate Immune System
|
- Degradation of the extracellular matrix
|
|
|
|
|
CFTR and SLC4A8 |
cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) |
solute carrier family 4, sodium bicarbonate cotransporter, member 8 |
- ABC-family proteins mediated transport
|
- Transport of inorganic cations/anions and amino acids/oligopeptides
- SLC-mediated transmembrane transport
- Bicarbonate transporters
|
- Bumetanide
- Glyburide
- Ibuprofen
- Adenosine-5\'-Diphosphate
- Phosphoaminophosphonic Acid-Adenylate Ester
- Phosphonoserine
- Crofelemer
- Ivacaftor
|
|
|
|
CLU and VHL |
clusterin |
von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
- Response to elevated platelet cytosolic Ca2+
- Platelet degranulation
- Platelet activation, signaling and aggregation
|
- Cellular response to hypoxia
- Antigen processing: Ubiquitination & Proteasome degradation
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
- Class I MHC mediated antigen processing & presentation
- Adaptive Immune System
|
|
|
|
|
CLU and TGFBR2 |
clusterin |
transforming growth factor, beta receptor II (70/80kDa) |
- Response to elevated platelet cytosolic Ca2+
- Platelet degranulation
- Platelet activation, signaling and aggregation
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
COL4A1 and DISC1 |
collagen, type IV, alpha 1 |
disrupted in schizophrenia 1 |
- Signaling by PDGF
- NCAM1 interactions
- Collagen formation
- Axon guidance
- Collagen degradation
- Anchoring fibril formation
- Non-integrin membrane-ECM interactions
- Degradation of the extracellular matrix
- Assembly of collagen fibrils and other multimeric structures
- Laminin interactions
- ECM proteoglycans
- Integrin cell surface interactions
- Collagen biosynthesis and modifying enzymes
- NCAM signaling for neurite out-growth
- Scavenging by Class A Receptors
|
|
|
|
|
|
CTNNA1 and PSEN1 |
catenin (cadherin-associated protein), alpha 1, 102kDa |
presenilin 1 |
- Cell junction organization
- Cell-cell junction organization
- CDO in myogenesis
- Myogenesis
- Signaling by VEGF
- Adherens junctions interactions
- VEGFR2 mediated vascular permeability
- VEGFA-VEGFR2 Pathway
|
- Degradation of the extracellular matrix
|
|
|
|
|
CTNND1 and PSEN1 |
catenin (cadherin-associated protein), delta 1 |
presenilin 1 |
- Cell junction organization
- Cell-cell junction organization
- Signaling by VEGF
- Adherens junctions interactions
- VEGFR2 mediated vascular permeability
- VEGFA-VEGFR2 Pathway
|
- Degradation of the extracellular matrix
|
|
|
|
|
CYP2C8 and PSEN1 |
cytochrome P450, family 2, subfamily C, polypeptide 8 |
presenilin 1 |
- Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
- Metabolism of lipids and lipoproteins
- Metabolic disorders of biological oxidation enzymes
- Phase 1 - Functionalization of compounds
- Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
- Arachidonic acid metabolism
- Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
- Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
- Cytochrome P450 - arranged by substrate type
- CYP2E1 reactions
- Biological oxidations
- Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
- Defective FMO3 causes Trimethylaminuria (TMAU)
- Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
- Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)
- Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
- Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
- Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
- Defective CYP1B1 causes Glaucoma
- Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
- Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
- Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
- Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
- Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
- Xenobiotics
- Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)
- Defective MAOA causes Brunner syndrome (BRUNS)
- Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
- Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
|
- Degradation of the extracellular matrix
|
|
|
|
|